ATE186641T1 - Cytokinhemmer - Google Patents

Cytokinhemmer

Info

Publication number: ATE186641T1
Authority: AT; Austria
Prior art keywords: production; inhibiting; cytokine inhibitors; mammal; interleukin
Prior art date: 1991-02-19

Application number

AT92907362T

Other languages

English (en)

Inventor

Alison Mary Badger

Wanda Bernadette High

Original Assignee

Anormed Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-19

Filing date

1992-02-18

Publication date

1999-12-15

1992-02-18 Application filed by Anormed Inc filed Critical Anormed Inc

1999-12-15 Application granted granted Critical

1999-12-15 Publication of ATE186641T1 publication Critical patent/ATE186641T1/de

Links

102000004127 Cytokines Human genes 0.000 title abstract 2
108090000695 Cytokines Proteins 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
230000002401 inhibitory effect Effects 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
102000000589 Interleukin-1 Human genes 0.000 abstract 1
108010002352 Interleukin-1 Proteins 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
SERHTTSLBVGRBY-UHFFFAOYSA-N atiprimod Chemical class C1CC(CCC)(CCC)CCC11CN(CCCN(CC)CC)CC1 SERHTTSLBVGRBY-UHFFFAOYSA-N 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT92907362T 1991-02-19 1992-02-18 Cytokinhemmer ATE186641T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US65757891A	1991-02-19	1991-02-19

Publications (1)

Publication Number	Publication Date
ATE186641T1 true ATE186641T1 (de)	1999-12-15

Family

ID=24637788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92907362T ATE186641T1 (de)	1991-02-19	1992-02-18	Cytokinhemmer

Country Status (14)

Country	Link
US (2)	US5602166A (de)
EP (1)	EP0572537B1 (de)
JP (1)	JP3162071B2 (de)
KR (1)	KR930702975A (de)
AT (1)	ATE186641T1 (de)
AU (1)	AU657745B2 (de)
CA (1)	CA2104214C (de)
DE (1)	DE69230314T2 (de)
DK (1)	DK0572537T3 (de)
ES (1)	ES2138595T3 (de)
GR (1)	GR3032612T3 (de)
IE (1)	IE920508A1 (de)
WO (1)	WO1992014462A1 (de)
ZA (1)	ZA921120B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9201804D0 (en) *	1992-01-28	1992-03-11	Smithkline Beecham Corp	Methods
GB9201803D0 (en) *	1992-01-28	1992-03-11	Smithkline Beecham Corp	Methods
GB9315306D0 (en) *	1993-07-23	1993-09-08	Smithkline Beecham Corp	Methods
GB9315351D0 (en) *	1993-07-23	1993-09-08	Smithkline Beecham Corp	Methods
GB9315340D0 (en) *	1993-07-23	1993-09-08	Smithkline Beecham Corp	Methods
US5594106A (en) *	1993-08-23	1997-01-14	Immunex Corporation	Inhibitors of TNF-α secretion
GB9414902D0 (en) *	1994-07-23	1994-09-14	Smithkline Beecham Corp	Methods
BR9601909A (pt) *	1995-07-13	1999-10-13	Smithkline Beecham Corp	N,n-dietil-8,8-dipropil-2-azaspiro(4,5)decano-2-propan amina dimaleato
US5939450A (en) *	1995-07-13	1999-08-17	Anormed Inc.	N,N-dimethyl-8,8-dipropyl-2-azaspiro 4.5!decane-2-propanamine dimaleate
NZ332627A (en) *	1996-05-17	2001-06-29	Anormed Inc	Use of substituted azaspirane in the treatment of asthma
GB2309167A (en) *	1997-05-10	1997-07-23	Anormed Inc	The use of azaspiranes in the treatment of Alzheimer's disease
CO5200760A1 (es) *	1999-06-16	2002-09-27	Smithkline Beecham Corp	Antagonistas del receptor de la il-8 ceptor il-8
CO5190696A1 (es) *	1999-06-16	2002-08-29	Smithkline Beecham Corp	Antagonistas de los receptores il-8
US6184246B1 (en)	1999-07-30	2001-02-06	The United States Of America As Represented By The Secretary Of Agriculture	Inhibition of cytokine production by polymethoxylated flavones
WO2002080970A1 (en) *	2001-03-23	2002-10-17	Regents Of The University Of California	Method for inhibiting articular cartilage matrix calcification
US7674838B2 (en) *	2002-04-05	2010-03-09	Henkel Corporation	Curable foam elastomeric compositions
WO2004080408A2 (en) *	2003-03-10	2004-09-23	Callisto Pharmaceuticals, Inc.	Method of treating cancer with azaspirane compositions
WO2010091381A2 (en) *	2009-02-09	2010-08-12	Callisto Pharmaceuticals, Inc.	An intermittent dosing strategy for treating rheumatoid arthrtis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3106552A (en)	1960-07-19	1963-10-08	Geschickter Fund Med Res	Nu-substituted azaspiranes and azaspirane-diones and processes for their preparation
US4963557A (en) *	1987-09-28	1990-10-16	Smithkline Beecham Corporation	Immunomodulatory azaspiranes
BR8907457A (pt)	1988-05-27	1991-04-02	Synergen Inc	Inibidores de interleucina-1

1992
- 1992-02-17 ZA ZA921120A patent/ZA921120B/xx unknown
- 1992-02-18 DE DE69230314T patent/DE69230314T2/de not_active Expired - Fee Related
- 1992-02-18 WO PCT/US1992/001283 patent/WO1992014462A1/en not_active Ceased
- 1992-02-18 AT AT92907362T patent/ATE186641T1/de not_active IP Right Cessation
- 1992-02-18 AU AU14633/92A patent/AU657745B2/en not_active Ceased
- 1992-02-18 CA CA002104214A patent/CA2104214C/en not_active Expired - Fee Related
- 1992-02-18 EP EP92907362A patent/EP0572537B1/de not_active Expired - Lifetime
- 1992-02-18 IE IE050892A patent/IE920508A1/en not_active IP Right Cessation
- 1992-02-18 ES ES92907362T patent/ES2138595T3/es not_active Expired - Lifetime
- 1992-02-18 DK DK92907362T patent/DK0572537T3/da active
- 1992-02-18 KR KR1019930702468A patent/KR930702975A/ko not_active Ceased
- 1992-02-18 JP JP50732392A patent/JP3162071B2/ja not_active Expired - Fee Related
1993
- 1993-10-15 US US08/138,178 patent/US5602166A/en not_active Expired - Lifetime
1997
- 1997-01-07 US US08/779,418 patent/US5900430A/en not_active Expired - Fee Related
2000
- 2000-02-09 GR GR20000400311T patent/GR3032612T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0572537B1 (de)	1999-11-17
EP0572537A1 (de)	1993-12-08
JPH06505483A (ja)	1994-06-23
KR930702975A (ko)	1993-11-29
CA2104214C (en)	2004-04-27
CA2104214A1 (en)	1992-08-20
US5900430A (en)	1999-05-04
EP0572537A4 (de)	1993-10-14
ZA921120B (en)	1993-01-27
IE920508A1 (en)	1992-08-26
DE69230314T2 (de)	2000-02-24
AU657745B2 (en)	1995-03-23
DE69230314D1 (de)	1999-12-23
WO1992014462A1 (en)	1992-09-03
ES2138595T3 (es)	2000-01-16
DK0572537T3 (da)	2000-03-27
GR3032612T3 (en)	2000-05-31
US5602166A (en)	1997-02-11
JP3162071B2 (ja)	2001-04-25
AU1463392A (en)	1992-09-15

Legal Events

Date	Code	Title	Description
2000-03-15	UEP	Publication of translation of european patent specification
2010-11-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE186641T1 (de)	1999-12-15	Cytokinhemmer
NO20001583D0 (no)	2000-03-27	Stimulering av hematopoetiske celler in vitro
NO942618L (no)	1994-08-30	Imidazolderivater og deres anvendelse som cytokin-inhibitorer
FI981437A7 (fi)	1998-08-25	PDE III, PDE IV ja TNF inhibiittoreina käyttökelpoisia imidejä
NO975716L (no)	1998-02-04	Imidazolforbindelser
EP0715619A4 (de)	1997-03-19	Inhibitoren der tnf-alpha sekretion
MY131298A (en)	2007-08-30	5-heteroyl indole derivatives
NO326660B1 (no)	2009-01-26	Imidazolyl-cykliske acetal forbindelser, farmasøytiske sammensetninger inneholdende disse forbindelser og anvendelse av forbindelsene
NO930509D0 (no)	1993-02-12	Lavdensitets broennsement som kan fjernes med syre, og metoder
DK1213015T3 (da)	2006-08-14	Oralt farmaceutisk præparat med forsinket frigivelse af protonpumpeinhibitorer
DK0912192T3 (da)	2002-12-02	Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
DK0527879T3 (da)	1997-07-14	Synergistiske terapeutiske præparater og fremgangsmåder.
TR199802676A2 (xx)	1999-11-22	T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
DE59200089D1 (de)	1994-04-21	Hochdruckentladungslampe kleiner Leistung.
ATE252885T1 (de)	2003-11-15	Plan zur verabreichung von h+, k+-atpase inhibitoren
GB8907305D0 (en)	1989-05-17	High slew rate linear amplifier
DE69535961D1 (de)	2009-07-16	T-zellaktivierung
KR950703064A (ko)	1995-08-23	세포증식의 저해물질, 그의 제조방법 및 이용방법
NO890046L (no)	1989-07-21	Disubstituerte pyridiner.
IT8420506U1 (it)	1985-07-13	Dispositivo di regolazione e di posizionamento per una poltrona.
ATE59553T1 (de)	1991-01-15	Polyhydroxybenzoesaeure-abkoemmlinge.
ITTO910787A0 (it)	1991-10-18	Amplificatore di potenza, in particolare di tipo audio
FI962264A0 (fi)	1996-05-30	Tulehduksia aiheuttavan sytokiinin muodostumisen inhibiittori, joka käsittää polyprenyylin johdannaisia aktiivisena ainesosana
ES2078501T3 (es)	1995-12-16	Metodo para el tratamiento de la trombocitopenia y composiciones farmaceuticas utiles para el mismo.
DE69025337D1 (de)	1996-03-21	Tumor-nekrose-faktor-antagonist